Treatment of Severe Infectious Purpura in Children with Human Plasma from Donors Immunized with Escherichia coli J5: A Prospective Double-Blind Study

Publisher Website
Google Scholar
Abstract
To evaluate the efficacy of anti-J5 serum in the treatment of severe infectious purpura, 73 children were randomized to receive either anti-J5 (40) or control (33) plasma. Age, blood pressure, and biologic risk factors were similar in both groups. At admission, however, tumor necrosis factor serum concentrations were 974 ± 173 pg/ml compared with 473 ± 85 pg/ml (P = .023) and interleukin-6 serum concentrations were 129 ± 45 compared with 19 ± 5 ng/ml (P = .005) in the control and treated groups, respectively. The duration ofshock and the occurrence of complications were similar in both groups. The mortality rate was 36% in the control group and 25% in the treated group (P = .317; odds ratio, 0.76; 95% confidence interval, 0.46–1.26). This trend disappeared after correction for unbalances in risk factors at randomization using a logistic regression model. These results suggest that anti-j5 plasma did not affect the course or mortality of severe infectious purpura in children.

This publication has 0 references indexed in Scilit: